Soluble receptor for advanced glycation end products (sRAGE) as a biomarker of COPD.

Aged Biomarkers / blood Female Forced Expiratory Volume Humans Longitudinal Studies Lung / diagnostic imaging Male Middle Aged Phenotype Pulmonary Disease, Chronic Obstructive / blood Pulmonary Emphysema / blood Receptor for Advanced Glycation End Products / blood Severity of Illness Index Spirometry Tomography, X-Ray Computed Vital Capacity
Biomarkers COPD Emphysema Progression

Journal

Respiratory research
ISSN: 1465-993X
Titre abrégé: Respir Res
Pays: England
ID NLM: 101090633

Informations de publication

Date de publication:
27 Apr 2021
Historique:
received: 18 12 2020
accepted: 16 03 2021
entrez: 28 4 2021
pubmed: 29 4 2021
medline: 24 11 2021
Statut: epublish

Résumé

Soluble receptor for advanced glycation end products (sRAGE) is a proposed emphysema and airflow obstruction biomarker; however, previous publications have shown inconsistent associations and only one study has investigate the association between sRAGE and emphysema. No cohorts have examined the association between sRAGE and progressive decline of lung function. There have also been no evaluation of assay compatibility, receiver operating characteristics, and little examination of the effect of genetic variability in non-white population. This manuscript addresses these deficiencies and introduces novel data from Pittsburgh COPD SCCOR and as well as novel work on airflow obstruction. A meta-analysis is used to quantify sRAGE associations with clinical phenotypes. sRAGE was measured in four independent longitudinal cohorts on different analytic assays: COPDGene (n = 1443); SPIROMICS (n = 1623); ECLIPSE (n = 2349); Pittsburgh COPD SCCOR (n = 399). We constructed adjusted linear mixed models to determine associations of sRAGE with baseline and follow up forced expiratory volume at one second (FEV Lower plasma or serum sRAGE values were associated with a COPD diagnosis (P < 0.001), reduced FEV Lower blood sRAGE is associated with more severe airflow obstruction and emphysema, but associations with progression are inconsistent in the cohorts analyzed. In these cohorts, genotype influenced sRAGE measurements and strengthened variance modelling. Thus, genotype should be included in sRAGE evaluations.

Sections du résumé

BACKGROUND BACKGROUND
Soluble receptor for advanced glycation end products (sRAGE) is a proposed emphysema and airflow obstruction biomarker; however, previous publications have shown inconsistent associations and only one study has investigate the association between sRAGE and emphysema. No cohorts have examined the association between sRAGE and progressive decline of lung function. There have also been no evaluation of assay compatibility, receiver operating characteristics, and little examination of the effect of genetic variability in non-white population. This manuscript addresses these deficiencies and introduces novel data from Pittsburgh COPD SCCOR and as well as novel work on airflow obstruction. A meta-analysis is used to quantify sRAGE associations with clinical phenotypes.
METHODS METHODS
sRAGE was measured in four independent longitudinal cohorts on different analytic assays: COPDGene (n = 1443); SPIROMICS (n = 1623); ECLIPSE (n = 2349); Pittsburgh COPD SCCOR (n = 399). We constructed adjusted linear mixed models to determine associations of sRAGE with baseline and follow up forced expiratory volume at one second (FEV
RESULTS RESULTS
Lower plasma or serum sRAGE values were associated with a COPD diagnosis (P < 0.001), reduced FEV
CONCLUSIONS CONCLUSIONS
Lower blood sRAGE is associated with more severe airflow obstruction and emphysema, but associations with progression are inconsistent in the cohorts analyzed. In these cohorts, genotype influenced sRAGE measurements and strengthened variance modelling. Thus, genotype should be included in sRAGE evaluations.

Identifiants

DOI: 10.1186/s12931-021-01686-z PMID: 33906653 PMC: PMC8076883
pubmed: 33906653
doi: 10.1186/s12931-021-01686-z
pii: 10.1186/s12931-021-01686-z
pmc: PMC8076883
doi:

Substances chimiques

AGER protein, human 0
Biomarkers 0
Receptor for Advanced Glycation End Products 0

Types de publication

Journal Article Meta-Analysis

Langues

eng

Sous-ensembles de citation

IM

Pagination

127

Subventions

Organisme : NHLBI NIH HHS
ID : HHSN268200900017C
Pays : United States
Organisme : NHLBI NIH HHS
ID : HHSN268200900018C
Pays : United States
Organisme : NHLBI NIH HHS
ID : HHSN268200900014C
Pays : United States
Organisme : NHLBI NIH HHS
ID : HHSN268200900020C
Pays : United States
Organisme : NHLBI NIH HHS
ID : R21HL129917
Pays : United States
Organisme : NHLBI NIH HHS
ID : HHSN268200900016C
Pays : United States
Organisme : NHLBI NIH HHS
ID : HHSN268200900019C
Pays : United States
Organisme : NHLBI NIH HHS
ID : Number U01 HL089856
Pays : United States
Organisme : NHLBI NIH HHS
ID : U01 HL137880
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL137995
Pays : United States
Organisme : NHLBI NIH HHS
ID : U01 HL089897
Pays : United States
Organisme : NHLBI NIH HHS
ID : U24 HL141762
Pays : United States
Organisme : NHLBI NIH HHS
ID : HHSN268200900013C
Pays : United States
Organisme : NHLBI NIH HHS
ID : P50HL084948
Pays : United States
Organisme : NIEHS NIH HHS
ID : P30 ES005605
Pays : United States
Organisme : NHLBI NIH HHS
ID : HHSN268200900015C
Pays : United States
Organisme : NIDDK NIH HHS
ID : P30 DK054759
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL129937
Pays : United States

Références

Nat Genet. 2019 Mar;51(3):481-493
pubmed: 30804560
J Diabetes Complications. 2015 Mar;29(2):180-5
pubmed: 25499973
Thorax. 2014 May;69(5):491-4
pubmed: 24029743
Lancet Respir Med. 2013 Apr;1(2):129-36
pubmed: 24429093
J Diabetes Complications. 2011 May-Jun;25(3):168-74
pubmed: 20685137
PLoS One. 2015 Jun 17;10(6):e0128452
pubmed: 26083729
Biogerontology. 2019 Jun;20(3):279-301
pubmed: 30968282
COPD. 2010 Feb;7(1):32-43
pubmed: 20214461
PLoS One. 2015 Mar 17;10(3):e0118979
pubmed: 25781626
Am J Respir Crit Care Med. 2017 Feb 15;195(4):473-481
pubmed: 27579823
BMC Pulm Med. 2014 Apr 24;14:68
pubmed: 24758342
PLoS Genet. 2016 Aug 17;12(8):e1006011
pubmed: 27532455
Crit Care. 2008;12(1):201
pubmed: 18226173
Diabetes Care. 2009 Jul;32(7):1218-20
pubmed: 19366975
Respir Res. 2014 Oct 12;15:127
pubmed: 25306249
Thorax. 2017 May;72(5):400-408
pubmed: 28174340
Am J Respir Cell Mol Biol. 2013 Jul;49(1):128-34
pubmed: 23526218
Cell. 1999 Jun 25;97(7):889-901
pubmed: 10399917
Int J Angiol. 2016 Jun;25(2):110-6
pubmed: 27231427
Shock. 2018 Oct;50(4):472-482
pubmed: 29040215
Am J Respir Crit Care Med. 2015 Oct 1;192(7):785-92
pubmed: 26132989
Dis Markers. 2019 Feb 4;2019:2067353
pubmed: 30863465
PLoS One. 2011;6(11):e27416
pubmed: 22087311
Ann Am Thorac Soc. 2017 May;14(5):628-635
pubmed: 28248552
Diabetes. 2001 Dec;50(12):2792-808
pubmed: 11723063
Nat Commun. 2018 Aug 15;9(1):3268
pubmed: 30111768
Eur Respir J. 2014 Feb;43(2):421-9
pubmed: 23794464
Respir Res. 2017 Jun 13;18(1):117
pubmed: 28610627
Biochim Biophys Acta. 2007 Oct;1770(10):1468-74
pubmed: 17714874
J Gen Virol. 2013 Aug;94(Pt 8):1691-1700
pubmed: 23559480
Talanta. 2018 May 15;182:414-421
pubmed: 29501172
Cell Signal. 2013 Nov;25(11):2185-97
pubmed: 23838007
Respir Med. 2018 Dec;145:21-27
pubmed: 30509711
Diabetes. 2013 Jun;62(6):2116-21
pubmed: 23396398
Clin Chem. 2017 May;63(5):980-989
pubmed: 28280052
Atherosclerosis. 2012 Jan;220(1):208-14
pubmed: 21906738
Diabetologia. 2019 Jul;62(7):1268-1274
pubmed: 31127314
Eur Respir J. 2008 Apr;31(4):869-73
pubmed: 18216052
Am J Respir Crit Care Med. 2013 Oct 15;188(8):948-57
pubmed: 23947473
Metabolism. 2007 Feb;56(2):199-205
pubmed: 17224333
Nat Genet. 2017 Mar;49(3):426-432
pubmed: 28166215
Eur Respir J. 2012 Mar;39(3):721-9
pubmed: 21920897
Nat Genet. 2017 Mar;49(3):416-425
pubmed: 28166213
Nat Genet. 2019 Mar;51(3):494-505
pubmed: 30804561
Arch Physiol Biochem. 2008 Apr;114(2):111-9
pubmed: 18615900

Auteurs

Katherine A Pratte (KA)

Department of Biostatistics, National Jewish Health, Denver, CO, USA.

Jeffrey L Curtis (JL)

Department of Internal Medicine, University of Michigan Health System, Ann Arbor, MI, USA.
Medical Service, Ann Arbor Healthcare System, Ann Arbor, MI, USA.

Katerina Kechris (K)

Department of Biostatistics and Informatics, School of Public Health, University of Colorado Denver, Anschutz Medical Campus, Aurora, CO, USA.

David Couper (D)

Department of Biostatistics, Collaborative Studies Coordinating Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.

Michael H Cho (MH)

Channing Division of Network Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Boston, MA, USA.

Edwin K Silverman (EK)

Channing Division of Network Medicine, Brigham and Women's Hospital, Boston, MA, USA.

Dawn L DeMeo (DL)

Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Boston, MA, USA.

Frank C Sciurba (FC)

Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.

Yingze Zhang (Y)

Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.

Victor E Ortega (VE)

Center for Genomics and Personalized Medicine Research, Wake Forest School of Medicine, Winston-Salem, NC, USA.

Wanda K O'Neal (WK)

Marsico Lung Institute (CF Research Center), University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.

Lucas A Gillenwater (LA)

Division of Pulmonary Medicine, Department of Medicine, National Jewish Health, 1400 Jackson Street, Denver, CO, 80206, USA.
Computational Bioscience Program, University of Colorado Anschutz Medical Campus, Aurora, CO, 80045, USA.

David A Lynch (DA)

Department of Radiology, National Jewish Health, Denver, CO, USA.

Eric A Hoffman (EA)

Department of Radiology and Biomedical Engineering, University of Iowa, Iowa City, IA, USA.

John D Newell (JD)

Department of Radiology and Biomedical Engineering, University of Iowa, Iowa City, IA, USA.

Alejandro P Comellas (AP)

Department of Internal Medicine, College of Medicine, University of Iowa Carver, Iowa City, IA, USA.

Peter J Castaldi (PJ)

Channing Division of Network Medicine, Brigham and Women's Hospital, Boston, MA, USA.

Bruce E Miller (BE)

COPD Foundation, Miami, FL, USA.

Simon D Pouwels (SD)

Department of Pathology and Medical Biology, University of Groningen, Groningen, Netherlands.

Nick H T Ten Hacken (NHTT)

Department of Pathology and Medical Biology, University of Groningen, Groningen, Netherlands.

Rainer Bischoff (R)

Department of Analytical Biochemistry, University of Groningen, Groningen, Netherlands.

Frank Klont (F)

Department of Analytical Biochemistry, University of Groningen, Groningen, Netherlands.

Prescott G Woodruff (PG)

Division of Pulmonary, Critical Care, Sleep and Allergy, Department of Medicine, University of California-San Francisco, San Francisco, CA, USA.
Cardiovascular Research Institute, University of California-San Francisco, San Francisco, CA, USA.

Robert Paine (R)

Division of Pulmonary and Critical Care, University of Utah, Salt Lake City, UT, USA.

R Graham Barr (RG)

Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, Columbia University, New York, NY, USA.

John Hoidal (J)

Division of Pulmonary and Critical Care, University of Utah, Salt Lake City, UT, USA.

Claire M Doerschuk (CM)

Marsico Lung Institute (CF Research Center), University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.

Jean-Paul Charbonnier (JP)

Thirona, LungQ, Nijmegen, Netherlands.

Ruby Sung (R)

Research and Development, GlaxoSmithKline, Collegeville, PA, USA.

Nicholas Locantore (N)

Research and Development, GlaxoSmithKline, Collegeville, PA, USA.

John G Yonchuk (JG)

Research and Development, GlaxoSmithKline, Collegeville, PA, USA.

Sean Jacobson (S)

Department of Genetics, National Jewish Health, Denver, CO, USA.

Ruth Tal-Singer (R)

COPD Foundation, Miami, FL, USA.

Debbie Merrill (D)

COPD Foundation, Miami, FL, USA.

Russell P Bowler (RP)

Division of Pulmonary Medicine, Department of Medicine, National Jewish Health, 1400 Jackson Street, Denver, CO, 80206, USA. BowlerR@NJHealth.org.
ORCID: 0000-0003-4651-363X

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

Recherchemedicale.com › Personnes › Tranches d'âge › Adulte › Sujet âgé › Soluble receptor for advanced glycation end...
Recherchemedicale.com › Facteurs biologiques › Marqueurs biologiques › Soluble receptor for advanced glycation end...
Recherchemedicale.com › Phénomènes physiologiques respiratoires et circulatoires › Phénomènes physiologiques respiratoires › Ventilation pulmonaire › Volume expiratoire maximal par seconde › Soluble receptor for advanced glycation end...
Recherchemedicale.com › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Soluble receptor for advanced glycation end...
Recherchemedicale.com › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études longitudinales › Soluble receptor for advanced glycation end...
Recherchemedicale.com › Appareil respiratoire › Poumon › Soluble receptor for advanced glycation end...
Recherchemedicale.com › Personnes › Tranches d'âge › Adulte › Adulte d'âge moyen › Soluble receptor for advanced glycation end...
Recherchemedicale.com › Phénomènes génétiques › Phénotype › Soluble receptor for advanced glycation end...
Recherchemedicale.com › États, signes et symptômes pathologiques › Processus pathologiques › Caractéristiques de la maladie › Maladie chronique › Broncho-pneumopathie chronique obstructive › Soluble receptor for advanced glycation end...
Recherchemedicale.com › États, signes et symptômes pathologiques › Processus pathologiques › Caractéristiques de la maladie › Maladie chronique › Broncho-pneumopathie chronique obstructive › Emphysème pulmonaire › Soluble receptor for advanced glycation end...
Recherchemedicale.com › Facteurs biologiques › Médiateurs de l'inflammation › Récepteur spécifique des produits finaux de glycosylation avancée › Soluble receptor for advanced glycation end...
Recherchemedicale.com › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Collecte de données › Enquêtes et questionnaires › Enquêtes de santé › Indicateurs d'état de santé › Acuité des besoins du patient › Indice de gravité de la maladie › Soluble receptor for advanced glycation end...
Recherchemedicale.com › Diagnostic › Techniques et procédures diagnostiques › Techniques de diagnostic respiratoire › Tests de la fonction respiratoire › Spirométrie › Soluble receptor for advanced glycation end...
Recherchemedicale.com › Diagnostic › Techniques et procédures diagnostiques › Imagerie diagnostique › Tomographie › Tomographie à rayons X › Tomodensitométrie › Soluble receptor for advanced glycation end...
Recherchemedicale.com › Phénomènes physiologiques respiratoires et circulatoires › Phénomènes physiologiques respiratoires › Capacité pulmonaire totale › Capacité vitale › Soluble receptor for advanced glycation end...